The American Association of Neurological Surgeons, describes a traumatic brain injury (TBI) as a blow to the head or a penetrating head injury that disrupts the normal function of the brain. TBI can result when the head suddenly and violently hits an object or when an object pierces the skull and enters brain tissue.
The trauma to society is that about 1.7 million cases of TBI occur in the U.S. every year, and approximately 5.3 million people live with a disability caused by TBI in the U.S. alone.
Enter oSLO, Oxidized SLO, is an oxidized variation of a genetically engineered clone of streptolysin-O (SLO), the bacterial toxin which causes strep throat pain. Oxidation of SLO renders it non-toxic and in so doing, changes both the structure and function of the molecule.
oSLO’s targeted treatment is for chronic traumatic brain injury (cTBI), potentially reversing many of the cognition, motor, memory, mood, and personality deficits that define this condition. oSLO functions as a biological signal molecule that helps restore normal cellular communication and downregulate inflammation.
Research conducted by Beech Tree Labs has shown that oSLO regulates genes associated with inflammation, scarring, healing and it addresses many of the obstacles that have blocked the successful development of other cTBI drug candidates. A biological drug candidate like oSLO is robust, however, as it simultaneously down-regulates genes that cause inflammation as well as up-regulates other genes that are anti-inflammatory in function.
In a mouse study of acute traumatic brain injury conducted at Harvard Medical School, oSLO reduced gliosis (a proliferation of cells leading to scarring) in the treatment group. The study also demonstrated that oSLO helped restore memories in concussed mice to approximately the same level as non-concussed mice at the end of a multi-day treatment and testing period.
Join us as John Michael, President of Resolys Bio, the creator of oSLO shares how physicians at Brown University have been the first to apply the technology treat approximately 25 patients with cTBI over the last 3+ years. The results, oSLO has proven completely safe for every patient and reversed the condition in 90% of those treated. One patient sums up this miracle by saying, “It gave me my life back!”
ABOUT JOHN MCMICHAEL, PhD
Dr. John M0cMichael, Co-Chairman & Chief Scientific Officer of Resolys Bio, a privately-held pharmaceutical company formed by B0eech Tree Labs, Inc. of which he is also Founder and CEO.
McMichael developed the world’s first live-virus fish vaccines for use in fish populations, and is an Alzheimer’s disease pioneer, ha0ving licensed 30+ patents to Elan Corp. plc, to support their Alzheimer’s initiative. He now holds more than 100 pa0tents with twice that pending worldwide. His experience also includes:
Among his 0.many outstanding credits are having served as: Professor of Biology and Health Sciences, Edinboro University of Pennsylvania; General Manager for ImmunoTherapeutics, where he licensed a veterinary anti-inflammatory product to Eudomonics, Inc., which launched and continues to sell the product; Vice President of Molecular Rx, Inc., a biopharmaceutical company focused on products for managing inflammatory responses; Founder and President of Milkhaus Laboratory, Inc., a company now focused on botanical agents for nutraceutical use; and Founder and President of The Institute for Therapeutic Discovery, a not-for-profit organization focusing on the interplay between biochemistry and biophysics in the course and management of health and disease.
